This project plans to establish an organoid chip model of prostate cancer patients with internal organ metastasis from surgical or biopsy tissue sources, and test the sensitivity of commonly used chemotherapy drugs based on organoid chip drug sensitivity testing technology to screen out sensitive individualized treatment plans.
Patients with visceral metastasis of prostate cancer diagnosed clinically or pathologically;
Age ≥ 18 years old;
ECOG score ≤ 2 points or ECOG score 3-4 points due to tumor progression;
Normal liver and kidney function, serum transaminase ALT<66 U/L, AST<36 U/L, total bilirubin<22 umol/L, creatinine<106 umol/L, urea nitrogen<6.1 mmol/L; Normal bone marrow function: neutrophil count ≥ 1800/mm3 and platelet count ≥ 100000/mm3;
Patients with severe heart, liver, kidney, and peripheral nervous system diseases, as well as autoimmune diseases such as hyperthyroidism and hypothyroidism; Systemic lupus erythematosus, etc;
Patients who are unable to obtain tissue samples;
Subjects with active pulmonary tuberculosis (TB);
Subjects who are preparing for or have previously undergone tissue/organ transplantation;